Form 8-K - Current report:
SEC Accession No. 0001104659-24-019866
Filing Date
2024-02-13
Accepted
2024-02-13 16:05:38
Documents
14
Period of Report
2024-02-12
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm246109d1_8k.htm   iXBRL 8-K 21448
  Complete submission text file 0001104659-24-019866.txt   189731

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rvlpq-20240212.xsd EX-101.SCH 3018
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvlpq-20240212_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvlpq-20240212_pre.xml EX-101.PRE 22360
15 EXTRACTED XBRL INSTANCE DOCUMENT tm246109d1_8k_htm.xml XML 3381
Mailing Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807
Business Address 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 9088091300
RVL Pharmaceuticals plc (Filer) CIK: 0001739426 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38709 | Film No.: 24625738
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)